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Rationale: Idiopathic pulmonary fibrosis (IPF) and other idiopathic
interstitial pneumonias (IIPs) have similar clinical and radiographic
features, but their histopathology, response to therapy, and natural
history differ. A surgical lung biopsy is often required to distinguish
between these entities.
Objectives: We sought to determine if clinical variables could predict
a histopathologic diagnosis of IPF in patients without honeycomb
change on high-resolution computed tomography (HRCT).
Methods: Data from 97 patients with biopsy-proven IPF and 38
patients with other IIPs were examined. Logistic regression models
were built to identify the clinical variables that predict histopatho-
logic diagnosis of IPF.
Measurements and Main Results: Increasing age and average total
HRCT interstitial score on HRCT scan of the chest may predict
a biopsy confirmation of IPF. Sex, pulmonary function, presence
of desaturation, or distance walked during a 6-minute walk test
did not help discriminate pulmonary fibrosis from other IIPs.
Conclusions: Clinical data may be used to predict a diagnosis of IPF
over other IIPs. Validation of these data with a prospective study is
needed.
Keywords: idiopathic pulmonary fibrosis; idiopathic interstitial pneu-
monia; diagnosis; computed tomography of the chest
Idiopathic interstitial pneumonias (IIPs), including idiopathic
pulmonary fibrosis (IPF), are characterized by chronic dyspnea,
interstitial infiltrates on radiographs, reduced lung volumes, and
impaired diffusion capacity of the lung (DLCO) (1). There is
considerable overlap in the clinical features (2) of the IIPs,
although the histopathologic features differ (1). An accurate
diagnosis is critical as the response to treatment and prognosis
differs between IIPs, with IPF having the worst prognosis (3–5).
Difficulty in diagnostic separation between these entities has
been emphasized by several groups (6–8), highlighting the need
to optimize the diagnostic evaluation.
The diagnosis of IPF is confirmed when appropriate clinical
and radiographic features are seen in combination with a surgi-
cal lung biopsy showing a pattern of usual interstitial pneumo-
nia (UIP). In an appropriate clinical setting, a diagnosis of IPF
can be made without a surgical lung biopsy when definitive
high-resolution computed tomography (HRCT) scan features
are present (8–10). Definitive features of UIP on HRCT include
subpleural reticulation with a basal predominance and honey-
combing with an absence of extensive ground glass abnormality,
micronodules, discrete cysts, mosaic attenuation/air trapping,
or consolidation (8–11). Unfortunately, many patients do not
have definitive radiographic features of UIP, leaving a wide
differential diagnosis and the requirement for a surgical lung
biopsy. IPF is ultimately diagnosed in a large proportion
of these patients based on the histopathologic finding of UIP
(3). Unfortunately, many patients who present with fibrotic
lung disease are elderly and have important comorbidities
that increase the risk of a surgical lung biopsy (12–15). We
hypothesized that a combination of clinical and radiological
features could be used to accurately predict a diagnosis of IPF
confirmed by surgical lung biopsy. Some of the results of these
studies have been previously reported in the form of an abstract
(16, 17).
METHODS
This is a retrospective study of 135 patients with biopsy-proven IPF/UIP
(n 5 97) or other IIPs (n 5 38) from our database who did not have
honeycomb change on HRCT. A total of 644 patients with evidence of
fibrotic lung disease were enrolled sequentially into protocols investi-
gating the etiology, diagnosis, and treatment of fibrotic lung disease
from 1995 to 2006 (Figure 1). Patients without a surgical lung biopsy or
in whom there was evidence of underlying connective tissue disease (ie,
clinical diagnosis and/or specific serology and/or clear symptoms of
connective tissue disease) or other cause of interstitial disease were
excluded. Data were extracted for those patients with HRCT, pulmo-
nary function testing (PFT), and 6-minute walk test (6MWT) within 6
months of the lung biopsy. Patients with evidence of pulmonary fibrosis
but without honeycombing on HRCT (HRCT interstitial score ,2)
were then selected for data analysis (see below). A final diagnosis was
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Scientific Knowledge on the Subject
Idiopathic interstitial pneumonias (IIPs), including idio-
pathic pulmonary fibrosis (IPF), share many clinical and
radiographic features. However, their histopathology, re-
sponse to therapy, and natural history differ. A surgical
lung biopsy is often required to differentiate early IPF from
other non-IPF IIPs.
What This Study Adds to the Field
Age and total HRCT interstitial score on an HRCT scan of
the chest may predict a diagnosis of biopsy-confirmed IPF
over non-IPF IIPs. This study provides clinical variables
that may be used to predict IPF over non-IPF IIPs, thus
saving some patients from a surgical lung biopsy.
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established using a clinical/radiological/pathological diagnostic schema
that we have previously described (18).
HRCT scans were scored by two expert thoracic radiologists using
a semiquantitative scale that assesses the degree of ground glass
attenuation (HRCT alveolar score) and fibrotic change (HRCT in-
terstitial score) (19) (Table 1 and Figure 2). Radiologists were blinded
to the diagnosis. Agreement between the radiologists was very good
(kappa 5 0.727; 95% confidence interval [CI], 0.641–0.813). It is im-
portant to recognize that an HRCT interstitial score of less than 2 in all
lobes identifies patients without any honeycomb change on HRCT.
Pulmonary function studies and 6MWT were performed as described
(20, 21). 6MWT data include the distance walked and whether the
patient’s oxygen saturation fell below 88% during the test.
Baseline demographic data, pulmonary function, 6MWT, and
HRCT scores were compared between patients with IPF and non-
IPF IIP using the Student t test for continuous variables (22) and the
chi-square test for categorical variables (23), except where indicated.
Univariate and multivariate logistic models were constructed to de-
termine which variables predict a diagnosis of IPF. The quality of the
prediction models was evaluated using receiver operating characteris-
tics (ROC) analysis with the area under the curve calculated (24). The
positive predictive values (PPVs), specificities, sensitivities, and nega-
tive predictive values (NPVs) for new patients with different risk
profiles were examined based on the final model. Statistical analysis
was performed with R 2.8.0 software (http://www.r-project.org/).
RESULTS
We examined data from 97 patients with biopsy-proven IPF and
38 patients with other IIPs (nonspecific interstitial pneumonia,
19; hypersensitivity pneumonia, 9; respiratory bronchiolitis in-
terstitial lung disease/desquamative interstitial pneumonia, 9;
and cryptogenic organizing pneumonia, 1). Patients with IPF
were significantly older, marginally more likely to be female,
and had similar smoking histories. They had more fibrosis and
less ground glass on HRCT. Pulmonary function and 6MWT
results were similar between the groups (Table 2).
Univariate logistic regression models of demographic,
HRCT, pulmonary function, and 6MWT variables were gener-
ated to determine which variables predict a diagnosis of IPF.
Older patient age, lower HRCT alveolar scores, and higher
HRCT interstitial scores were significant predictors of an IPF
diagnosis (Table 3). Multivariate logistic regression models
were used to determine variables that individually contribute
toward prediction of IPF. From these analyses, increasing age
(OR, 1.09 per year; 95% CI, 1.04–1.14; P 5 0.0007) and
increasing average HRCT interstitial score (OR, 10.44 per unit
increase in score; 95% CI, 3.12–34.91; P 5 0.0001) best
predicted a diagnosis of IPF.
Age and HRCT interstitial scores were examined in detail
for their ability to predict a diagnosis of IPF. Increasing age
was a powerful predictor of IPF. Age of at least 70 years was
associated with a PPV for IPF of at least 95% (Table 4). When
HRCT interstitial score was combined with age the ability to
predict the presence of IPF improved and could be expanded
to even younger patients (Table 5). The likelihood ratio for
this model is 40.73 (P , 0.001). For example, a patient aged 50
years or older with an HRCT interstitial score of at least 0.8
had a PPV of IPF of at least 97%. ROC analyses were per-
formed for the model with age alone and the model with age
combined with HRCT interstitial score (data not shown). The
areas under the ROC curves were 0.77 and 0.84, respectively,
for these two models, with P , 0.0001 for improved prediction
based on the model including HRCT interstitial score. These
data demonstrate the potential clinical usefulness of semi-
quantitative HRCT scoring in aiding in the diagnosis of IPF.
For user convenience, we provide a probability of IPF score
(Table 6), which predicts the PPV, NPV, sensitivity, and speci-
ficity of a diagnosis of IPF based on a patient’s age and HRCT
interstitial score using the formula:
TABLE 1. HIGH-RESOLUTION COMPUTED TOMOGRAPHY SCORING SYSTEM (19)
Score Alveolar Interstitial
0 No alveolar disease No interstitial disease
1 Ground glass opacity ,5% of lobe Septal thickening but no honeycomb
2 Ground glass opacity ,25% of lobe Honeycomb change ,25% of lobe
3 Ground glass opacity 25–49% of lobe Honeycomb change 25–49% of lobe
4 Ground glass opacity 50–75% of lobe Honeycomb change 50–75% of lobe
5 Ground glass opacity .75% of lobe Honeycomb change .75% of lobe
Radiologists score each lobe and then take an average of all the lobes for the final HRCT scores.
Figure 1. CONSORT diagram illustrating the selection of patients in-
cluded in the data analysis. CTD-ILD 5 connective tissue disease–related
interstitial lung disease; HRCT 5 high-resolution computed tomography;
IIP 5 idiopathic interstitial pneumonia; IPF 5 idiopathic pulmonary
fibrosis; PFT 5 pulmonary function tests; 6MWT 5 6-minute walk test.
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probability of IPF score5½ð0:0843Age1 2:3463HRCT
interstitial score2 3:31Þ=5:856
(truncate negative values as 0; positive values .1 as 1)
The distribution of the probability of IPF scores for patients
in this study is shown in Figure 3.
The probability of IPF score can be used to estimate the
probability of IPF for an individual patient. For example, if
a patient has an average HRCT interstitial score of 0.8 and is 50
years old, the probability of IPF score would be 0.5 correspond-
ing to a PPV of 86% for the presence of IPF. If the same patient
is 70 years old, the probability of IPF score would be 0.8 and the
PPV for the presence of IPF is 100%.
DISCUSSION
Differentiating between IPF and non-IPF IIPs is clinically
relevant and in some cases can be accomplished without
a surgical lung biopsy (9, 10). In this study we examined the
ability of clinical variables to predict a histopathologic pattern
of UIP in a group of patients without a diagnostic HRCT
study—patients who traditionally would require a surgical lung
biopsy to obtain a definitive diagnosis. We identified increased
age and HRCT interstitial score as important discriminators
between IPF and non-IPF IIPs. These data provide practical,
important information in the evaluation of patients with sus-
pected IPF. If validated, these data will allow the clinician to
estimate the probability that a patient with suspected IPF will
have IPF confirmed by surgical lung biopsy by the simple
measure of patient’s age and average HRCT interstitial score.
As older patients often have comorbidities and increased risk of
operative morbidity we believe these data will be useful in
helping patients and caregivers weigh the risks, benefits, and
usefulness of surgical lung biopsy for the diagnosis of suspected
IPF or non-IPF IIP. If validated, these data may also allow for
a broader inclusion of patients into clinical trials (i.e., those
patients unable to tolerate a surgical lung biopsy and with
consistent but not definite HRCT criteria for the diagnosis of
IPF).
The probability of IPF was increased in older patients
consistent with published incidence and prevalence data (25).
We extend these data by defining specific test characteristics
(sensitivity, specificity, PPV, and NPV) for finding UIP/IPF at
biopsy compared with non-IPF IIP for specific age values. Using
age as a sole predictor a cutoff of 75 years was associated with
TABLE 2. BASELINE DEMOGRAPHIC AND CLINICAL VARIABLES OF 97 PATIENTS WITH BIOPSY-PROVEN
IDIOPATHIC PULMONARY FIBROSIS AND 38 PATIENTS WITH NON–IDIOPATHIC PULMONARY FIBROSIS
IDIOPATHIC INTERSTITIAL PNEUMONIA
IPF (n 5 97) Non-IPF IIP (n 5 38) P Value
Age, yr 62 6 9 52 6 9 ,0.0001
Sex, male/female 40 (41%)/57 (59%) 22 (58%)/16 (42%) 0.08
Smoking status,
never/ever-smoker
32 (35%)/60 (65%)* 15 (41%)/22 (59%)†
HRCT scores
HRCT alveolar score 1.72 6 0.95 2.29 6 1.32 0.02
HRCT interstitial score 0.91 6 0.29 0.54 6 0.39 ,0.001
Pulmonary function
FVC, % predicted 65 6 16 70 6 19 0.15
DLCO, % predicted 48 6 17 50 6 17 0.57
6MWT
Distance walked, ft 911 6 473 895 6 578 0.92
Desaturation , 88%‡ 45 (46%) 6 (16%) 0.47
Definition of abbreviations: DLCO 5 diffusion capacity for carbon monoxide; HRCT 5 high-resolution computed tomography;
IIP 5 idiopathic interstitial pneumonia; IPF 5 idiopathic pulmonary fibrosis; 6MWT 5 6-minute walk test.
All patients had an HRCT interstitial score less than 2 in all lobes.
* Missing data for five patients.
† Missing data for one patient.
‡ Number of patients whose oxygen saturation fell below 88% during the 6MWT.
Figure 2. Examples of varied high-
resolution computed tomography
(HRCT) alveolar and HRCT intersti-
tial scores. Each panel is from a dif-
ferent patient. The scores for each
panel are for the image that is
displayed. Scores are represented
as alveolar/interstitial. LLL 5 left
lower lobe; LUL 5 left upper lobe;
RLL5 right lower lobe; RUL5 right
upper lobe.
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a 100% predictive value of confirming IPF by surgical lung
biopsy; 70 years was nearly as good, with a PPV of 95%. These
findings are consistent with evolving pathobiologic paradigms of
IPF as a degenerative disease of aging (26, 27). Our finding that
increased age is a strong predictor of IPF in patients with
relatively early radiographic manifestations of disease (no
honeycomb change) lends some support for this concept.
It is established that HRCT can accurately predict the
presence of UIP at biopsy when features of honeycombing in
a basilar, peripheral distribution (without a predominance of
ground glass or other features to suggest an alternative di-
agnosis) are present (1, 10, 28, 29). Our data extend these
finding by demonstrating that even modest amounts of fibrosis,
without honeycombing, can be highly predictive of the presence
of IPF when combined with the patient’s age.
We were unable to identify any physiologic variables that
helped predict the presence of IPF. In aggregate, patients with
IPF tend to be older and have more pronounced physiologic
derangements (21, 28–30); however, there is a significant over-
lap between these features between patients with IPF and non-
IPF IIP (30). This overlap likely explains the lack of predictive
ability for these variables.
We found the best predictive model for finding IPF was an
easy-to-calculate probability of IPF score that combined age
with the HRCT interstitial score. Using this score, patients 55
years of age or older with even modest amounts of fibrosis
(average HRCT interstitial scores of 0.8–1.0) were associated
with a PPV of 100% for confirming IPF at surgical lung biopsy.
Review of the data in Table 6 suggests that a cutoff probability
of IPF score could be derived, above which there would be
a reasonable PPV and NPV for a diagnosis of IPF based on age
and HRCT interstitial score. However, these data should be
confirmed with a validation cohort before the probability of IPF
TABLE 3. UNIVARIATE LOGISTIC REGRESSION MODELS OF
VARIABLES PREDICTING A DIAGNOSIS OF IDIOPATHIC
PULMONARY FIBROSIS
OR (95% CI) P Value
Age 1.11 (1.06, 1.16) ,0.0001
Male sex 1.96 (0.92, 4.19) 0.08
Ever smoker 1.28 (0.58, 2.80) 0.54
HRCT score
HRCT alveolar score 0.61 (0.43, 0.87) 0.007
HRCT interstitial score 17.20 (5.41, 54.70) ,0.0001
Pulmonary function
FVC % predicted 0.18 (0.02, 1.59) 0.12
DLCO % predicted 0.48 (0.04, 6.01) 0.57
6MWT Variables
Desaturation ,88% 0.63 (0.20, 1.93) 0.41
Distance per 1,000 ft 1.06 (0.35, 3.26) 0.91
Definition of abbreviations: CI 5 confidence interval; DLCO 5 diffusion capacity
for carbon monoxide; HRCT 5 high-resolution computed tomography scan of
the chest; OR 5 odds ratio; 6MWT 5 6-minute walk test.
TABLE 4. POSITIVE PREDICTIVE VALUE, SPECIFICITY,
SENSITIVITY, AND NEGATIVE PREDICTIVE VALUE WHEN
CLASSIFYING PATIENTS WITH IDIOPATHIC PULMONARY
FIBROSIS BASED ON BEING AT LEAST AS OLD AS THE
AGE INDICATED
Age (yr) PPV Specificity Sensitivity NPV
30 72 0 100 NA
35 72 5 99 67
40 74 11 98 67
45 74 16 95 55
50 78 34 92 62
55 83 58 80 54
60 87 76 61 43
65 91 89 43 38
70 95 97 21 32
75 100 100 6 29
80 100 100 1 28
Definition of abbreviations: NA 5 not applicable; NPV 5 negative predictive
value; PPV 5 positive predictive value.
Data expressed as percentages.
TABLE 5. POSITIVE PREDICTIVE VALUE, SPECIFICITY,
SENSITIVITY, AND NEGATIVE PREDICTIVE VALUE WHEN
CLASSIFYING PATIENTS WITH IDIOPATHIC PULMONARY
FIBROSIS BASED ON BEING AT LEAST AS OLD AS THE AGE
INDICATED AND HAVING A HIGH-RESOLUTION COMPUTED
TOMOGRAPHY INTERSTITIAL SCORE AT LEAST AS HIGH
AS INDICATED
Age
HRCT
Interstitial
Score PPV Specificity Sensitivity NPV
30 0.2 72 0 100 NA
0.4 72 0 100 NA
0.6 73 5 99 67
0.8 76 24 97 75
1.0 85 61 88 66
35 0.2 72 0 100 NA
0.4 72 0 100 NA
0.6 74 11 98 67
0.8 82 50 92 70
1.0 90 79 73 54
40 0.2 72 0 100 NA
0.4 72 0 100 NA
0.6 76 24 97 75
0.8 86 66 84 61
1.0 97 97 32 36
45 0.2 72 0 100 NA
0.4 73 5 99 65
0.6 81 42 94 73
0.8 92 84 70 52
1.0 100 100 7 30
50 0.2 72 0 100 NA
0.4 73 8 98 60
0.6 85 61 88 66
0.8 97 97 32 36
1.0 100 100 1 28
55 0.2 72 0 100 NA
0.4 74 13 97 63
0.6 87 68 81 59
0.8 100 100 8 30
1.0 100 100 1 28
60 0.2 72 0 100 NA
0.4 76 24 97 75
0.6 92 84 70 52
>0.8 100 100 1 28
65 0.2 72 0 100 NA
0.4 78 32 96 75
0.6 96 95 45 40
>0.8 100 100 1 28
70 0.2 72 0 100 NA
0.4 82 50 92 70
0.6 100 100 24 34
>0.8 100 100 1 28
75 0.2 72 0 100 NA
0.4 85 61 88 66
0.6 100 100 7 30
>0.8 100 100 1 28
80 0.2 0 0 100 NA
0.4 66 66 84 61
>0.6 100 100 1 28
Definition of abbreviations: HRCT 5 high-resolution computed tomography;
NA 5 not applicable; NPV 5 negative predictive value; PPV 5 positive predictive
value.
Data expressed as percentages.
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score is used clinically. Until then, patients who do not meet
clinical criteria for the diagnosis of IPF following the American
Thoracic Society/European Respiratory Society guidelines (28)
should undergo an open lung biopsy to establish the diagnosis.
Strengths of this study include the inclusion of a diverse
group of patients typical of those who present to the clinician
with suspected IIP as well as a detailed clinical, radiographic,
and pathologic approach to diagnosis (18). This study is limited
by the lack of a validation cohort, by involving only a single
center, and by using radiologists who are experienced in the
scoring of HRCT studies. The prevalence of IPF in our cohort
was 79%, higher than that found in other studies (10, 31). How
these data apply to other academic and community practices
needs further study. Until emerging genomic and proteomic
tools to accurately diagnose IIPS become available, refining
current clinical-radiographic-physiologic assessments is needed
to improve diagnostic accuracy. This diagnostic accuracy will
also be crucial in future clinical trials because the underlying
pathogenetic mechanisms and responses to specific treatment
modalities are likely to be distinctly different in IPF versus non-
IPF IIPs.
In conclusion, we have shown that a higher HRCT in-
terstitial score and older age are predictive of a diagnosis of
IPF. In patients without honeycomb change on HRCT, older
age and modest amounts of fibrosis are highly predictive of
a diagnosis of IPF. Physiological variables, including FVC,
DLCO, and 6MWT variables, are not predictive of an IPF
diagnosis. Validation of these findings, preferably with a pro-
spective multicentre study, is needed before they can be applied
broadly.
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